+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 44 Pages
  • November 2022
  • GlobalData
  • Star Pharma
  • ID: 1495440
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Starpharma Holdings Ltd (SPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company's development programs include its DEP drug delivery, which is built around dendrimers and VivaGel portfolio. Its flagship product candidate, VivaGel, is a gel-based formulation for the treatment and prevention of bacterial vaginosis (BV) and it is also used as a vaginal microbicide to prevent sexually transmitted infections including HIV and genital herpes. It has license arrangements with several partners including Okamoto Industries and AstraZeneca among others. The company has research facilities in Melbourne, Australia. Starpharma is headquartered in Abbotsford, Victoria, Australia

Starpharma Holdings Ltd Key Recent Developments

  • Jun 27, 2022: Starpharma signs expanded DEP research agreement with US Biopharma Co
  • Apr 27, 2022: Starpharma to present DEP at Boston ADC summit
  • Feb 24, 2022: Dr Jeff Davies appointed as non-executive director
  • Dec 08, 2021: Starpharma Holdings: US biopharma DEP research agreement - additional information

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Starpharma Holdings Ltd - Key Facts
  • Starpharma Holdings Ltd - Key Employees
  • Starpharma Holdings Ltd - Key Employee Biographies
  • Starpharma Holdings Ltd - Major Products and Services
  • Starpharma Holdings Ltd - History
  • Starpharma Holdings Ltd - Company Statement
  • Starpharma Holdings Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Starpharma Holdings Ltd - Business Description
  • Other Break-up: Interest Revenue
  • Performance
  • Other Break-up: Other Income
  • Performance
  • Other Break-up: Revenue from contracts with customers
  • Performance
  • Starpharma Holdings Ltd - SWOT Analysis
  • SWOT Analysis - Overview
  • Starpharma Holdings Ltd - Strengths
  • Starpharma Holdings Ltd - Weaknesses
  • Starpharma Holdings Ltd - Opportunities
  • Starpharma Holdings Ltd - Threats
  • Starpharma Holdings Ltd - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Starpharma Holdings Ltd, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 27, 2022: Starpharma signs expanded DEP research agreement with US Biopharma Co
  • Apr 27, 2022: Starpharma to present DEP at Boston ADC summit
  • Feb 24, 2022: Dr Jeff Davies appointed as non-executive director
  • Dec 08, 2021: Starpharma Holdings: US biopharma DEP research agreement - additional information
  • Oct 28, 2021: Starpharma to present DEP at US Drug Delivery Conference
  • Jul 28, 2021: Starpharma : Lynda Cheng appointed as non-executive director
  • Jul 27, 2021: Starpharma to present DEP platform at CRS Annual Meeting
  • May 11, 2021: VIRALEZE partners with Harlequins in the UK
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Starpharma Holdings Ltd, Key Facts
  • Starpharma Holdings Ltd, Key Employees
  • Starpharma Holdings Ltd, Key Employee Biographies
  • Starpharma Holdings Ltd, Major Products and Services
  • Starpharma Holdings Ltd, History
  • Starpharma Holdings Ltd, Subsidiaries
  • Starpharma Holdings Ltd, Key Competitors
  • Starpharma Holdings Ltd, Annual Ratios
  • Starpharma Holdings Ltd, Interim Ratios
  • Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
  • Starpharma Holdings Ltd, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Starpharma Holdings Ltd, Performance Chart (2018 - 2022)
  • Starpharma Holdings Ltd, Ratio Charts
  • Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
  • Starpharma Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Proudex Australia Pty Ltd
  • ResApp Health Ltd
  • Immuron Ltd
  • iNova Pharmaceuticals (Australia) Pty Ltd
  • Sanonda Australia Pty Ltd
  • GLYDE Health Pty Ltd
  • Rhinomed Ltd
  • iNova Pharmaceuticals (Australia) Pty Ltd
  • ResApp Health Ltd
  • Immuron Ltd
  • GLYDE Health Pty Ltd
  • Sanonda Australia Pty Ltd
  • Proudex Australia Pty Ltd
  • Rhinomed Ltd